NCT00540553View on ClinicalTrials.gov

Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Healthy SubjectsAndrogen Deficiency

Interventions

DRUG

placebo

DRUG

GSK971086

Trial Locations (1)

47714

GSK Investigational Site, Evansville

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY